Lawrence Fong, MD of University of California, San Francisco explains how there are several combination therapies to study, but not enough patient-participants for these clinical trials. He hopes for a more rational path regarding patients in order to see which combination therapies will work. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.
Immunotherapy Combination Studies Need Rational Path Considering Patient Population
